Michael Kelly

Jul 18, 2024 | nature.com | Maryam Yamadi |James Phelan |Michael Kelly |Ryan Young |Stefania Pittaluga |Sriranjani Darbha | +1 more

AbstractGerminal centers (GCs) that form in mucosal sites are exposed to gut-derived factors that have the potential to influence homeostasis independent of antigen receptor-driven selective processes. The G-protein Gα13 confines B cells to the GC and limits the development of GC-derived lymphoma. We discovered that Gα13-deficiency fuels the GC reaction via increased mTORC1 signaling and Myc protein expression specifically in the mesenteric lymph node (mLN).

Mar 18, 2024 | cgtlive.com | Michael Kelly

“We’ve come a long way in the last 10 years that I've been with the organization. A decade ago, there were no clinical trials. Today, we've got a handful of really meaningful therapies that are impacting patients, and I believe the pathway over the next 2 to 3 years is going to be even more exciting. [We have] newer technologies, more muscle-tropic capsids, non-AAV technologies. Right now, it’s about delivery, we've got the tools available in order to go after RNA, DNA and various other things.

Feb 7, 2024 | cgtlive.com | Michael Kelly

"Non-AAV viruses are an important way of where the field is moving today. And that allows us to get away from not just the neutralizing antibodies, but ways to deal with redosing that we think it's going to be a concern over the next few years and ways to deal with the limitations that we've got with size of products that have been carried.

Nov 8, 2023 | cgtlive.com | Michael Kelly

“I think it's the best of both worlds right now. There are companies that are clinically active right now examining new ways to enhance exon skipping by targeting muscle, so you can actually improve the efficiency of exon skipping.This is an exciting time.

Sep 18, 2023 | cgtlive.com | Michael Kelly

“Some of the concerns that we have today are with these very high dose serious adverse events, that's one of the challenges with Duchenne. When you think that the body is comprised of 40 to 60% muscle – the amount of AAV that we need to put in the body in order to target all the different muscle groups is extremely high. And so, approaches like Solid’s, where we're using a new AAV are insular, where we're changing the actual route of administration, hold significant promise.